Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy
Among new treatment approaches for patients with cancer, few have accelerated as quickly
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …
Pathogenesis of triple-negative breast cancer
F Derakhshan, JS Reis-Filho - Annual Review of Pathology …, 2022 - annualreviews.org
Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of
fundamentally different diseases with different histologic, genomic, and immunologic …
fundamentally different diseases with different histologic, genomic, and immunologic …
Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a rare cancer, characterized by high metastatic
potential and poor prognosis, and has limited treatment options. The current standard of …
potential and poor prognosis, and has limited treatment options. The current standard of …
Multi-omic machine learning predictor of breast cancer therapy response
Breast cancers are complex ecosystems of malignant cells and the tumour
microenvironment. The composition of these tumour ecosystems and interactions within …
microenvironment. The composition of these tumour ecosystems and interactions within …
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer
In triple-negative breast cancer (TNBC), the benefit of combining chemotherapy with
checkpoint inhibitors is still not very clear. We utilize single-cell RNA-and ATAC-sequencing …
checkpoint inhibitors is still not very clear. We utilize single-cell RNA-and ATAC-sequencing …
Deep learning in histopathology: the path to the clinic
Abstract Machine learning techniques have great potential to improve medical diagnostics,
offering ways to improve accuracy, reproducibility and speed, and to ease workloads for …
offering ways to improve accuracy, reproducibility and speed, and to ease workloads for …
Spatial biology of cancer evolution
Z Seferbekova, A Lomakin, LR Yates… - Nature Reviews …, 2023 - nature.com
The natural history of cancers can be understood through the lens of evolution given that the
driving forces of cancer development are mutation and selection of fitter clones. Cancer …
driving forces of cancer development are mutation and selection of fitter clones. Cancer …
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer
Immune-checkpoint blockade (ICB) combined with neoadjuvant chemotherapy improves
pathological complete response in breast cancer. To understand why only a subset of …
pathological complete response in breast cancer. To understand why only a subset of …
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
C Denkert, F Seither, A Schneeweiss, T Link… - The Lancet …, 2021 - thelancet.com
Background The development of anti-HER2 antibody–drug conjugates opens new
therapeutic options for patients with breast cancer, including patients with low expression of …
therapeutic options for patients with breast cancer, including patients with low expression of …
Spatial predictors of immunotherapy response in triple-negative breast cancer
Immune checkpoint blockade (ICB) benefits some patients with triple-negative breast
cancer, but what distinguishes responders from non-responders is unclear. Because ICB …
cancer, but what distinguishes responders from non-responders is unclear. Because ICB …